ActeaVentures GmbH. (2/21/17). "Press Release: ActeaVentures Successfully Assisted Neovacs in Partnering IFN-K for Lupus to BioSense Global for the Chinese Market". Karlsruhe.

	Region	China
	Organisation	ActeaVentures GmbH
	Organisation 2	Neovacs S.A. (Euronext Growth Paris: ALNEV)
	Group	Neovacs (Group)
	Product	consulting, business
	Product 2	IFNalpha-Kinoid (IFNa-Kinoïd)
	Index term	Neovacs–ActeaVentures: business consulting, 201702 supply service business development advisor for Neovacs license deal w BioSense Global LLC
	Index term 2	BioSense (US/CN)–Neovacs: IFNalpha Kinoid, 201702– license option agreem for China up to €65m of combined upfront + milestones + royalties
	Person	Parrisius, Jürgen (ActeaVentures 201403– Managing Partner before JP BioConsulting + Pfizer + Roche + Cardion)
	Person 2	Sieler, Miguel (Neovacs 201310 CEO before Bayer France CEO at Bayer since 1975)

ActeaVentures is pleased to announce the successful execution of another licensing agreement on behalf of the Paris based biopharmaceutical company Neovacs SA. ActeaVentures provided professional services to Neovacs in the partnering of its lead product IFN-K for the indications of Systemic Lupus Erythematosus (SLE) and Dermatomyositis (DM), to BioSense Global LLC.

“The opportunity to represent Neovacs in partnering its innovative Interferon-alpha Kinoid product currently in global phase 2b clinical trials is a special honor,” said Juergen Parrisius, Managing Partner and Co-Founder of ActeaVentures. “We are delighted that we could support Neovacs in closing this deal and believe that both Neovacs and BioSense will strongly benefit from this partnership in the growing and demanding Chinese market.”

Neovacs’ Managing Director and CEO, Miguel Sieler remarked: “We are very pleased with the advice and support of the ActeaVentures team in all phases of the BD&L process which led to concluding this agreement with our partner BioSense Global in an efficient and well-structured manner.”

Additional details regarding the transaction are provided in Neovacs’ press release:
[ http://neovacs.fr/wp-content/uploads/pr-21-02-17.pdf ]

Record changed: 2023-06-05